论文部分内容阅读
目的观察曲美他嗪(trimetazidine,TMZ)治疗肥厚型心肌病(hypertrophic cardiomyopathy,HCM)心力衰竭的疗效。方法将70例HCM患者随机分为对照组34例,治疗组36例。两组均给予常规抗心力衰竭治疗,治疗组在常规抗心力衰竭基础上加用TMZ20mg,3次/d口服,6个月为一个疗程。结果治疗组在常规抗心力衰竭基础上,明显地提高心力衰竭患者的6min步行距离(P<0.01),用药后左心室射血分数(LVEF)、每搏量(SV)以及每分排血量(CO)明显增加(P<0.05,P<0.01)。结论常规抗心力衰竭基础上加用曲美他嗪可提高疗效,改善了心肌的收缩功能,增加了患者的运动耐量,值得在临床上推广。
Objective To observe the curative effect of trimetazidine (TMZ) on heart failure of hypertrophic cardiomyopathy (HCM). Methods Seventy patients with HCM were randomly divided into control group (34 cases) and treatment group (36 cases). Both groups were given routine anti-heart failure treatment. The treatment group was given TMZ20mg on the basis of conventional anti-heart failure, 3 times / d orally, and 6 months as a course of treatment. Results On the basis of routine anti-heart failure, the treatment group significantly improved the 6-minute walking distance (P <0.01), left ventricular ejection fraction (LVEF), stroke volume (SV) (CO) increased significantly (P <0.05, P <0.01). Conclusion Conventional anti-heart failure combined with trimetazidine can improve the curative effect, improve the myocardial contractile function and increase the patient’s exercise tolerance, which is worth popularizing clinically.